tiprankstipranks
Arcus Biosciences Inc (RCUS)
NYSE:RCUS
US Market
RCUS
Arcus Biosciences
RESEARCH TOOLSreports
Want to see RCUS full AI Analyst Report?

Arcus Biosciences (RCUS) Stock Forecast & Price Target

541 Followers
See the Price Targets and Ratings of:

RCUS Analyst Ratings

Strong Buy
10Ratings
Strong Buy
8 Buy
2 Hold
0 Sell
Based on 10 analysts giving stock ratings to
Arcus
Biosciences
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

RCUS Stock 12 Month Forecast

Average Price Target

$35.56
▲(46.62% Upside)
Based on 10 Wall Street analysts offering 12 month price targets for Arcus Biosciences in the last 3 months. The average price target is $35.56 with a high forecast of $47.00 and a low forecast of $23.00. The average price target represents a 46.62% change from the last price of $24.25.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"6":"$6","27":"$27","48":"$48","16.5":"$16.5","37.5":"$37.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":47,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$47.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":35.55555555555555,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$35.56</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":23,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$23.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[6,16.5,27,37.5,48],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jul<br/>2025","6":"Oct<br/>2025","9":"Jan<br/>2026","12":"Apr<br/>2026","25":"Apr<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,21.84,23.775384615384617,25.71076923076923,27.646153846153847,29.58153846153846,31.516923076923078,33.45230769230769,35.387692307692305,37.323076923076925,39.25846153846154,41.19384615384615,43.12923076923077,45.06461538461539,{"y":47,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,21.84,22.895042735042736,23.95008547008547,25.005128205128205,26.060170940170938,27.115213675213674,28.170256410256407,29.225299145299143,30.28034188034188,31.335384615384612,32.390427350427345,33.44547008547008,34.50051282051282,{"y":35.55555555555555,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,21.84,21.92923076923077,22.018461538461537,22.107692307692307,22.196923076923078,22.286153846153844,22.375384615384615,22.464615384615385,22.553846153846155,22.643076923076922,22.732307692307693,22.821538461538463,22.91076923076923,{"y":23,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":7.71,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.62,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.22,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.36,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.16,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10.81,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":13.48,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 30,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":19.72,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 21,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":26.1,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 23,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":23.83,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":21.66,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":23.94,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":21.84,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Target$47.00Average Price Target$35.56Lowest Price Target$23.00
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Wedbush Analyst forecast on RCUS
Robert Driscoll
Wedbush
Wedbush
$41
Buy
69.07%
Upside
Reiterated
04/22/26
Analysts Offer Insights on Healthcare Companies: Equillium (NASDAQ: EQ), UnitedHealth (NYSE: UNH) and Arcus Biosciences (NYSE: RCUS)
Bank of America Securities Analyst forecast on RCUS
Jason Zemansky
Bank of America Securities
Bank of America Securities
$25
Hold
3.09%
Upside
Reiterated
04/21/26
Balanced Risk Profile After TIGIT Failure and Gilead Exit Supports Neutral Stance on Arcus
H.C. Wainwright Analyst forecast on RCUS
Emily Bodnar
H.C. Wainwright
H.C. Wainwright
$28→$32
Buy
31.96%
Upside
Reiterated
04/20/26
Analysts' Top Healthcare Picks: Arcus Biosciences (RCUS), Alto Neuroscience, Inc. (ANRO)
Goldman Sachs Analyst forecast on RCUS
Richard Law CFA
Goldman Sachs
Goldman Sachs
$28→$30
Buy
23.71%
Upside
Reiterated
04/20/26
Arcus Biosciences: Buy Rated on Pipeline Control, PD‑1 Backbone Validation, and Upside from Emerging I&I and RCC Programs
Leerink Partners Analyst forecast on RCUS
Daina Graybosch
Leerink Partners
Leerink Partners
$49→$47
Buy
93.81%
Upside
Reiterated
04/20/26
Analysts Offer Insights on Healthcare Companies: TScan Therapeutics (NASDAQ: TCRX) and Arcus Biosciences (NYSE: RCUS)
Mizuho Securities Analyst forecast on RCUS
Unknown Analyst
Mizuho Securities
Not Ranked
Mizuho Securities
$47
Buy
93.81%
Upside
Reiterated
03/24/26
Mizuho Securities Remains a Buy on Arcus Biosciences (RCUS)
Citi Analyst forecast on RCUS
Yigal Nochomovitz
Citi
Citi
$44→$45
Buy
85.57%
Upside
Assigned
03/05/26
Arcus Biosciences price target raised to $45 from $44 at CitiArcus Biosciences price target raised to $45 from $44 at Citi
Evercore ISI Analyst forecast on RCUS
Jonathan Miller
Evercore ISI
Evercore ISI
―
Buy
―
Reiterated
03/02/26
Evercore ISI Sticks to Their Buy Rating for Arcus Biosciences (RCUS)
Truist Financial Analyst forecast on RCUS
Asthika Goonewardene
Truist Financial
Truist Financial
$30
Buy
23.71%
Upside
Reiterated
02/27/26
Wall Street Analysts Are Bullish on Top Healthcare Picks
Wells Fargo Analyst forecast on RCUS
Eva Fortea Verdejo
Wells Fargo
Wells Fargo
$30→$23
Hold
-5.15%
Downside
Downgraded
02/12/26
Wells Fargo downgrades Arcus Biosciences (RCUS) to a Hold
Morgan Stanley Analyst forecast on RCUS
Terence Flynn
Morgan Stanley
Morgan Stanley
$23→$20
Hold
-17.53%
Downside
Downgraded
01/08/26
Arcus Biosciences downgraded to Equal Weight from Overweight at Morgan StanleyArcus Biosciences downgraded to Equal Weight from Overweight at Morgan Stanley
Barclays Analyst forecast on RCUS
Peter Lawson
Barclays
Barclays
$14
Buy
-42.27%
Downside
Reiterated
10/28/25
Arcus Biosciences (RCUS) Receives a Buy from Barclays
Cantor Fitzgerald Analyst forecast on RCUS
Li Watsek
Cantor Fitzgerald
Cantor Fitzgerald
―
Buy
―
Reiterated
10/08/25
Arcus Biosciences (RCUS) Gets a Buy from Cantor Fitzgerald
Analyst Type
Any
Any
Human Analysts
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Wedbush Analyst forecast on RCUS
Robert Driscoll
Wedbush
Wedbush
$41
Buy
69.07%
Upside
Reiterated
04/22/26
Analysts Offer Insights on Healthcare Companies: Equillium (NASDAQ: EQ), UnitedHealth (NYSE: UNH) and Arcus Biosciences (NYSE: RCUS)
Bank of America Securities Analyst forecast on RCUS
Jason Zemansky
Bank of America Securities
Bank of America Securities
$25
Hold
3.09%
Upside
Reiterated
04/21/26
Balanced Risk Profile After TIGIT Failure and Gilead Exit Supports Neutral Stance on Arcus
H.C. Wainwright Analyst forecast on RCUS
Emily Bodnar
H.C. Wainwright
H.C. Wainwright
$28→$32
Buy
31.96%
Upside
Reiterated
04/20/26
Analysts' Top Healthcare Picks: Arcus Biosciences (RCUS), Alto Neuroscience, Inc. (ANRO)
Goldman Sachs Analyst forecast on RCUS
Richard Law CFA
Goldman Sachs
Goldman Sachs
$28→$30
Buy
23.71%
Upside
Reiterated
04/20/26
Arcus Biosciences: Buy Rated on Pipeline Control, PD‑1 Backbone Validation, and Upside from Emerging I&I and RCC Programs
Leerink Partners Analyst forecast on RCUS
Daina Graybosch
Leerink Partners
Leerink Partners
$49→$47
Buy
93.81%
Upside
Reiterated
04/20/26
Analysts Offer Insights on Healthcare Companies: TScan Therapeutics (NASDAQ: TCRX) and Arcus Biosciences (NYSE: RCUS)
Mizuho Securities Analyst forecast on RCUS
Unknown Analyst
Mizuho Securities
Not Ranked
Mizuho Securities
$47
Buy
93.81%
Upside
Reiterated
03/24/26
Mizuho Securities Remains a Buy on Arcus Biosciences (RCUS)
Citi Analyst forecast on RCUS
Yigal Nochomovitz
Citi
Citi
$44→$45
Buy
85.57%
Upside
Assigned
03/05/26
Arcus Biosciences price target raised to $45 from $44 at CitiArcus Biosciences price target raised to $45 from $44 at Citi
Evercore ISI Analyst forecast on RCUS
Jonathan Miller
Evercore ISI
Evercore ISI
―
Buy
―
Reiterated
03/02/26
Evercore ISI Sticks to Their Buy Rating for Arcus Biosciences (RCUS)
Truist Financial Analyst forecast on RCUS
Asthika Goonewardene
Truist Financial
Truist Financial
$30
Buy
23.71%
Upside
Reiterated
02/27/26
Wall Street Analysts Are Bullish on Top Healthcare Picks
Wells Fargo Analyst forecast on RCUS
Eva Fortea Verdejo
Wells Fargo
Wells Fargo
$30→$23
Hold
-5.15%
Downside
Downgraded
02/12/26
Wells Fargo downgrades Arcus Biosciences (RCUS) to a Hold
Morgan Stanley Analyst forecast on RCUS
Terence Flynn
Morgan Stanley
Morgan Stanley
$23→$20
Hold
-17.53%
Downside
Downgraded
01/08/26
Arcus Biosciences downgraded to Equal Weight from Overweight at Morgan StanleyArcus Biosciences downgraded to Equal Weight from Overweight at Morgan Stanley
Barclays Analyst forecast on RCUS
Peter Lawson
Barclays
Barclays
$14
Buy
-42.27%
Downside
Reiterated
10/28/25
Arcus Biosciences (RCUS) Receives a Buy from Barclays
Cantor Fitzgerald Analyst forecast on RCUS
Li Watsek
Cantor Fitzgerald
Cantor Fitzgerald
―
Buy
―
Reiterated
10/08/25
Arcus Biosciences (RCUS) Gets a Buy from Cantor Fitzgerald
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
xxx
xxx
xxx
xxx
xxx
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Arcus Biosciences

3 Months
xxx
Success Rate
9/13 ratings generated profit
69%
Average Return
+14.28%
Copying xxxxxxxxxxxxxxxxxx
 trades and holding each position for 3 Months would result in 69.23% of your transactions generating a profit, with an average return of +14.28% per trade.
1 Year
Asthika GoonewardeneTruist Financial
Success Rate
8/13 ratings generated profit
62%
Average Return
+41.92%
Copying Asthika Goonewardene's trades and holding each position for 1 Year would result in 61.54% of your transactions generating a profit, with an average return of +41.92% per trade.
2 Years
xxx
Success Rate
13/13 ratings generated profit
100%
Average Return
+82.55%
Copying xxxxxxxxxxxxxxxxxx
 trades and holding each position for 2 Years would result in 100.00% of your transactions generating a profit, with an average return of +82.55% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

RCUS Analyst Recommendation Trends

Rating
Dec 25
Jan 26
Feb 26
Mar 26
Apr 26
Strong Buy
11
2
6
8
11
Buy
12
4
5
4
5
Hold
6
4
5
4
3
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
29
10
16
16
19
In the current month, RCUS has received 16 Buy Ratings, 3 Hold Ratings, and 0 Sell Ratings. RCUS average Analyst price target in the past 3 months is 35.56.
Each month's total comprises the sum of three months' worth of ratings.

RCUS Financial Forecast

RCUS Earnings Forecast

Next quarter’s earnings estimate for RCUS is -$0.88 with a range of -$1.08 to -$0.65. The previous quarter’s EPS was -$0.89. RCUS beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 56.87% of the time in the same period. In the last calendar year RCUS has Performed in-line its overall industry.
Next quarter’s earnings estimate for RCUS is -$0.88 with a range of -$1.08 to -$0.65. The previous quarter’s EPS was -$0.89. RCUS beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 56.87% of the time in the same period. In the last calendar year RCUS has Performed in-line its overall industry.

RCUS Sales Forecast

Next quarter’s sales forecast for RCUS is $29.48M with a range of $7.00M to $55.00M. The previous quarter’s sales results were $33.00M. RCUS beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.06% of the time in the same period. In the last calendar year RCUS has Performed in-line its overall industry.
Next quarter’s sales forecast for RCUS is $29.48M with a range of $7.00M to $55.00M. The previous quarter’s sales results were $33.00M. RCUS beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.06% of the time in the same period. In the last calendar year RCUS has Performed in-line its overall industry.

RCUS Stock Forecast FAQ

What is RCUS’s average 12-month price target, according to analysts?
Based on analyst ratings, Arcus Biosciences Inc’s 12-month average price target is 35.56.
    What is RCUS’s upside potential, based on the analysts’ average price target?
    Arcus Biosciences Inc has 46.62% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is RCUS a Buy, Sell or Hold?
          Arcus Biosciences Inc has a consensus rating of Strong Buy which is based on 8 buy ratings, 2 hold ratings and 0 sell ratings.
            What is Arcus Biosciences Inc’s price target?
            The average price target for Arcus Biosciences Inc is 35.56. This is based on 10 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst price target is $47.00 ,the lowest forecast is $23.00. The average price target represents 46.62% Increase from the current price of $24.25.
              What do analysts say about Arcus Biosciences Inc?
              Arcus Biosciences Inc’s analyst rating consensus is a Strong Buy. This is based on the ratings of 10 Wall Streets Analysts.
                How can I buy shares of RCUS?
                Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.